Automate Your Wheel Strategy on DVA
With Tiblio's Option Bot, you can configure your own wheel strategy including DVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DVA
- Rev/Share 154.2541
- Book/Share 15.0573
- PB -17.8169
- Debt/Equity -18.9525
- CurrentRatio 1.2917
- ROIC 0.1015
- MktCap 9511938000.0
- FreeCF/Share 10.6311
- PFCF 10.3917
- PE 15.9216
- Debt/Assets 0.7004
- DivYield 0
- ROE -1.5671
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
3 Warren Buffett-Style Stocks for a Golden Retirement
Published: February 04, 2026 by: 24/7 Wall Street
Sentiment: Neutral
Although former Berkshire Hathaway (NYSE:BRK-B) CEO Warren Buffett retired as the company's chief executive, his legacy looms large.
Read More
DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
DVA reports a fourth-quarter 2025 earnings and revenue beat as margins expanded and full-year adjusted EPS rose by double digits.
Read More
TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings
Published: February 03, 2026 by: Schwab Network
Sentiment: Positive
The AI trade is helping Teradyne (TER), with Diane King Hall pointing to the company's latest earnings as a signal of forward strength. Outside of tech, she notes DaVita's (DVA) earnings beat and guidance above expectations as it recovers from a malware attack.
Read More
DaVita: Some Success Is Possible, But Volatility Is Still Heavy
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive
DaVita (DVA) delivered a strong earnings beat, driving a 13.5%+ share price surge and reinforcing my positive outlook. DVA's strategy leverages home dialysis, integrated kidney care, and international expansion, supporting double-digit growth and margin stability despite sector headwinds. I maintain a fair value of $185/share and a price target of $130/share, reiterating a 'BUY' rating even after the recent upswing.
Read More
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
Published: February 02, 2026 by: Seeking Alpha
Sentiment: Neutral
DaVita Inc. (DVA) Q4 2025 Earnings Call Transcript
Read More
DaVita HealthCare (DVA) Q4 Earnings and Revenues Surpass Estimates
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
DaVita HealthCare (DVA) came out with quarterly earnings of $3.4 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $2.24 per share a year ago.
Read More
DaVita forecasts 2026 profit above estimates on steady dialysis service demand; shares jump
Published: February 02, 2026 by: Reuters
Sentiment: Positive
DaVita projected annual profit above estimates on Monday after reporting better-than-expected fourth-quarter results on steady demand for its kidney dialysis services, sending its shares up 13% in after-hours trading.
Read More
DaVita Inc. 4th Quarter 2025 Results
Published: February 02, 2026 by: PRNewsWire
Sentiment: Neutral
DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita.
Read More
Can Operational Execution Support DaVita's Q4 Performance?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
DVA's fourth-quarter 2025 performance is likely to have gained from technology upgrades, cost control and seasonal boosts despite ongoing volume headwinds.
Read More
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
Published: January 19, 2026 by: Zacks Investment Research
Sentiment: Positive
DVA stock benefits from a patient-centric model, third-quarter revenue growth and overseas expansion, though reliance on commercial payers remains a risk.
Read More
4 Outpatient Home Health Stocks in Focus as Market Dynamics Change
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.
Read More
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.
Read More
DaVita: More Volatile But Better Upside Than Fresenius
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Negative
DaVita (DVA) is rated a speculative 'Buy,' reflecting undervaluation despite recent earnings volatility. DVA's moat stems from its dominant US dialysis clinic network, but its reliance on Medicare reimbursement and lack of dividend heighten risk. Trading below 11.5x P/E, DVA offers potential double-digit annual returns if it reverts to historical valuation multiples.
Read More
Why Is DaVita HealthCare (DVA) Up 1.1% Since Last Earnings Report?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock?
Read More
DaVita Inc. (DVA) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Published: November 17, 2025 by: Seeking Alpha
Sentiment: Neutral
DaVita Inc. ( DVA ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 11:20 AM EST Company Participants Joel Ackerman - CFO & Treasurer Conference Call Participants Justin Lake - Wolfe Research, LLC Presentation Justin Lake Wolfe Research, LLC All right. Good morning.
Read More
DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Negative
DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.
Read More
Can Technology and Cost Discipline Lift DaVita's Q3 Earnings?
Published: October 28, 2025 by: Zacks Investment Research
Sentiment: Positive
DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.
Read More
3 Healthcare Stocks That Are Screaming Deals Right Now
Published: October 26, 2025 by: The Motley Fool
Sentiment: Positive
DaVita's recession-resistant business is growing internationally, but shares continue to trade at a heavily discounted valuation. Merck could be in for a major move if the pharma can soften the blow of an upcoming patent expiration.
Read More
DaVita HealthCare (DVA) is a Top-Ranked Growth Stock: Should You Buy?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
4 Outpatient Home Health Stocks Worth Watching Amid Shifting Trends
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
An aging global population and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DGX, DVA, ADUS and PNTG are well-poised to gain.
Read More
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
Largest kidney care research arm advances science to inform care delivery DENVER , Aug. 27, 2025 /PRNewswire/ -- As part of its 25th-anniversary celebration, DaVita, a leading provider of comprehensive kidney care, is proud to spotlight the groundbreaking work of its wholly owned research arm, DaVita Clinical Research (DCR). For a quarter-century, DCR has played a pivotal role in advancing kidney care — driving access to new therapies, improving clinical outcomes and shaping the future of nephrology through rigorous research and clinical trials.
Read More
Ransomware attack at dialysis firm DaVita affects 2.7 million people, US health dept website shows
Published: August 21, 2025 by: Reuters
Sentiment: Negative
A ransomware attack that encrypted certain elements of dialysis firm DaVita's network affected 2.7 million people, the U.S. health department's website showed on Thursday.
Read More
DaVita: Aggressive Buybacks Despite Rising Cost Of Debt
Published: August 20, 2025 by: Seeking Alpha
Sentiment: Positive
DaVita has reduced the share count by over 10% in the last six months, but interest expenses increased by 50% Y/Y. International revenues grew by 36% Y/Y, and DaVita is pending regulatory approval to close an acquisition from Fresenius Medical Care AG in Brazil. In the U.S., volumes declined by 1.1% Y/Y during Q2 2025 due to missed treatments caused by the severe flu season and the April cyber attack.
Read More
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Are Investors Undervaluing DaVita (DVA) Right Now?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
Read More
Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
DVA rides early momentum from phosphate binders ahead of second-quarter 2025 earnings, but PD supply issues may cloud growth.
Read More
DaVita HealthCare (DVA) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
DaVita HealthCare (DVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read More
About DaVita Inc. (DVA)
- IPO Date 1995-10-31
- Website https://www.davita.com
- Industry Medical - Care Facilities
- CEO Javier J. Rodriguez
- Employees 76000